Plasma fractionation is the process of separating plasma proteins from donated blood plasma for therapeutic and diagnostic uses. The key products derived include immunoglobulins, albumin, clotting factors, and other plasma-derived therapies. These products are critical for treating conditions such as immune deficiencies, hemophilia, and other blood disorders. The market growth is driven by increasing demand for plasma-derived therapies, rising prevalence of chronic diseases, and advancements in plasma fractionation technologies.
The global plasma fractionation market was valued at USD 28.66 billion in 2022, increasing at a CAGR of 7.07% from 2022 to 2030 and anticipated to reach USD 49.51 billion by 2030.
2. Recent Development
-
Advancements in chromatographic and filtration technologies enhancing purity and yield of plasma proteins.
-
Increased investments in plasma collection centers, particularly in North America and Europe.
-
Regulatory approvals for novel plasma-derived products and biosimilars.
-
Strategic mergers and acquisitions to expand production capabilities and market reach.
-
Development of recombinant and synthetic alternatives complementing plasma-derived therapies.
3. Market Dynamics
Drivers:
-
Rising prevalence of immune disorders and bleeding disorders globally.
-
Growing demand for plasma-derived therapies and increased patient awareness.
-
Expansion of plasma collection infrastructure, particularly in developed countries.
-
Technological advancements improving fractionation efficiency and product safety.
-
Increasing government initiatives and funding to support plasma donation and fractionation.
Restraints:
-
High costs associated with plasma collection and fractionation processes.
-
Stringent regulatory requirements affecting product approvals and market entry.
-
Limited plasma supply due to dependence on voluntary donations in some regions.
-
Risk of contamination and safety concerns impacting market growth.
Opportunities:
-
Growing demand for immunoglobulins and albumin in emerging markets.
-
Expansion of plasma fractionation applications in new therapeutic areas.
-
Development of innovative fractionation technologies such as nanofiltration.
-
Collaborations between plasma fractionators and biotech firms to develop new therapies.
Challenges:
-
Managing supply-demand imbalance due to limited plasma availability.
-
Maintaining product safety and efficacy amid evolving regulatory standards.
-
Addressing competition from synthetic and recombinant alternatives.
-
Ensuring cost-effective manufacturing while meeting quality standards.
4. Segment Analysis
Regional Segmentation Analysis:
-
North America: Dominates due to advanced healthcare infrastructure, high plasma collection rates, and favorable reimbursement policies.
-
Europe: Significant market share supported by established plasma fractionation facilities and growing demand.
-
Asia-Pacific: Emerging market with rising healthcare expenditure and increasing plasma donations.
-
Latin America and Middle East & Africa: Growing awareness and investment in healthcare infrastructure boosting market potential.
Type Segment Analysis:
-
Immunoglobulins: Used for treating immune deficiencies and autoimmune diseases.
-
Albumin: Used for volume replacement in surgeries and trauma cases.
-
Clotting Factors: Used in hemophilia and other bleeding disorders.
-
Other Plasma-derived Products: Including fibrinogen, alpha-1 antitrypsin, and others.
5. Some of the Key Market Players
-
Grifols, S.A.
-
CSL Limited
-
Octapharma AG
-
Takeda Pharmaceutical Company Limited
-
Baxter International Inc.
-
Kedrion S.p.A.
-
BioLife Plasma Services
-
Sanquin Blood Supply Foundation
-
LFB Group
These companies are investing in R&D, expanding plasma collection networks, and engaging in strategic partnerships to strengthen their market presence.
Request Sample PDF @ https://www.thebrainyinsights.com/enquiry/sample-request/13065
6. Report Description
The plasma fractionation market report offers an in-depth analysis of the global market, including market size, growth trends, and competitive landscape. It covers segmentation by product type and geography, technological advancements, and regulatory frameworks influencing the market. The report also profiles key players, their strategies, and recent developments. It serves as a valuable resource for healthcare providers, manufacturers, investors, and policymakers to understand market dynamics and make informed decisions.
Locked
